An oral anti-inflammatory therapy for Parkinson’s disease developed using artificial intelligence (AI) may be nearing clinical trials. Insilico Medicine said it plans to seek clearance later this year from the U.S. Food and Drug Administration (FDA) to advance the therapy, ISM8969, into human trials. The company said its…
Herantis Pharma announced that its Phase 1b clinical trial evaluating the safety and preliminary efficacy of HER-096, a potential disease-modifying therapy for Parkinson’s disease, has hit a key milestone: All dosing regimens and follow-up clinic visits have been completed. Top-line results from the trial (NCT06659562, EUCT2024-512532-30-00) —…
OM1 has expanded a real-world dataset of people with neurological conditions, including Parkinson’s disease, adding health records and clinical notes for 500,000 more people. “Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” Carl Marci, MD,…
Seal Rock Therapeutics has joined a Michael J. Fox Foundation (MJFF) initiative to develop therapies targeted at the LRRK2 gene for the treatment of Parkinson’s disease. The program, LRRK2 Investigative Therapeutics Exchange (LITE), brings together academic and industry collaborators to support preclinical and clinical development aimed…
A study showed that following the MIND diet — one that’s rich in vegetables, whole grains, legumes, nuts, and berries, and low in sugary, fried, and high-fat foods — may help maintain gut health in people with Parkinson’s disease by reducing the levels of zonulin, a protein that helps…
The Parkinson’s Foundation has announced that it will provide more than $4.3 million toward 44 research grants that seek to advance understanding of Parkinson’s disease and support efforts toward a cure. “The Parkinson’s Foundation is excited to support these brilliant scientists and see how they are approaching Parkinson’s…
Most people with Parkinson’s disease who’d experienced recurring falls found a personalized, home-based fall prevention program in Australia helpful for improving their safety and confidence. That’s according to a new assessment of the six-month program, dubbed Integrate, which was shown to reduce fall rates by nearly half among participants…
Continuous exposure to low-oxygen air halted neurodegeneration and eased or reversed motor symptoms in a mouse model of Parkinson’s disease, a study reports. “The results raise the possibility of an entirely new paradigm for addressing Parkinson’s,” Fumito Ichinose, MD, PhD, senior coauthor of the study, said in a…
ENERGI-F705PD, a potential disease-modifying therapy for Parkinson’s disease, was found to be safe and well tolerated in a Phase 1 clinical trial involving healthy volunteers, according to developer Energenesis Biomedical. Unlike currently available treatments, ENERGI-F705PD aims to address the causes of Parkinson’s and not just its symptoms.
Lysoway Therapeutics has received a $2.93-million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The funding will advance a potential new therapy that targets the TRPML1 protein, a promising approach designed to modify the disease’s progression rather than just treating symptoms. “This funding underscores growing…
Get regular updates to your inbox.
